Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Study Finds Weight Bearing CT Scans Could Provide Accurate Measurements of Adult Acquired Flatfoot Deformity

Gaining an accurate and complete measurement of the hindfoot alignment of a patient with adult acquired flatfoot deformity (AAFD) is difficult when using traditional clinical assessment. In a paper published in the journal Foot and Ankle Surgery, Dr. Cesar de Cesar Netto, MD, PhD, and his colleagues posit that weight-bearing cone beam computed tomography (CBCT)…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Gaining an accurate and complete measurement of the hindfoot alignment of a patient with adult acquired flatfoot deformity (AAFD) is difficult when using traditional clinical assessment. In a paper published in the journal Foot and Ankle Surgery, Dr. Cesar de Cesar Netto, MD, PhD, and his colleagues posit that weight-bearing cone beam computed tomography (CBCT) scanning technology may give a more complete, three-dimensional view of the deformity and its underlying causes.

In the article, “Hindfoot Alignment of Adult Acquired Flatfoot Deformity,” the team studied twenty patients with AAFD, twelve men and eight women. All participants had to undergo a clinical assessment of their hindfoot alignment and got a weight-bearing CBCT scan. After all tests were completed, the team found that the weight-bearing CBCT scans provided far more accurate, reliable and repeatable measurements than those of the clinical assessments, thus making a strong case for the use of cone beam technology in AAFD diagnosis and treatment.

In the video below, Dr. de Cesar Netto describes how WBCT assists in AAFD evaluation. “We have been finding really interesting things while studying the flat foot deformities in the weight bearing CT images, most of them related to coronal plane assessment. But it’s not just that,” Dr. Cesar de Netto says. “We are trying to use the three dimensional environment to find out how the deformity progresses.”

The problem with current practices, according to de Cesar Netto and his colleagues, is that they rely on two systems that make it difficult to obtain universally accepted results. The first is radiographic examinations. These are two-dimensional and cumbersome, with further difficulty added when trying to discern hindfoot alignment due to the complexity of the subtalar joint. Not only that, but these examinations are especially prone to improper positioning which would throw off the results. The other traditional system used for hindfoot alignment measurement is made up of a series of clinical measurements including simple visual evaluation. These measurements have consistently been shown to be inaccurate and highly variable from physician to physician.

Recent advancements in CBCT technology now allow physicians to obtain a three-dimensional, highly detailed view of a patient’s lower extremities. They also allow for a complete picture of both the soft-tissue and bone within the foot, so that no issues go overlooked. Of particular interest to the study at hand was the fact that CBCT allows for scans to be taken of the foot in a natural, weight-bearing state. As AFFD is highly dynamic, analysis of the condition with the effects of a patient’s full body weight can be immensely beneficial when developing a treatment plan.

Leading the way with weight-bearing cone beam technology is CurveBeam. The CurveBeam LineUP is revolutionizing how physicians approach diagnosis and treatment plan development as their technology provides complete views of the lower extremities with high image quality.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512